Biocon Biologics is planning to extend its biosimilar offerings in cancer with proposed biosimilars of Keytruda, Opdivo, and Herceptin SC. Thus, a $75+ billion cancer biosimilar market opportunity unfolds before Biocon. Additionally, the planned integration of Biocon Biologics as a wholly-owned subsidiary will enhance efficiency and visibility of earnings.